Skip to main content
Main navigation
Home
About pCPA
Who We Are
Governance
FAQs
Negotiations
Recent Updates
Forms and Publications
Brand Name Drugs
Negotiations Status
Negotiation Process
Generic Drugs
Biologics/Biosimilars
Contact Us
EN
FR
Daklinza (daclatasvir)
pCPA File Number:
21085
Negotiation Status:
Concluded with an LOI
Indication(s):
Chronic Hepatitis C
Sponsor/Manufacturer:
Bristol Myers Squibb Canada Inc.
CADTH Project Number:
Not Applicable
pCPA Engagement Letter Issued:
2016-07-22
Negotiation Process Concluded:
2017-02-17